SCHEMBL573852

SCHEMBL573852

CS(=O)(=O)Nc1ccc(C(=O)O)cc1OCC1CC1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.56
PDE4A P27815 8/20 0.48
PDE4B Q07343 8/20 0.48
PDE4C Q08493 8/20 0.48
PDE4D Q08499 8/20 0.48
NEU3 Q9UQ49 1/20 0.47
NR1H4 Q96RI1 2/20 0.45
MRGPRX1 Q96LB2 1/20 0.42
MAP4K4 O95819 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
BRD4 O60885 2/20 0.41
SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723405 1.00 CYP19A1 (0.56) CYP19A1PDE4APDE4BPDE4CPDE4D
SCHEMBL14481111 0.90 PDE4A (0.49) CYP19A1PDE4APDE4BPDE4CPDE4D
SCHEMBL2762046 0.89 CYP19A1 (0.55) CYP19A1PDE4APDE4BPDE4CPDE4D
SCHEMBL18830717 0.86 CYP19A1 (0.50) CYP19A1PDE4APDE4BPDE4CPDE4D
SCHEMBL18830796 0.86 CYP19A1 (0.50) CYP19A1PDE4APDE4BPDE4CPDE4D
SCHEMBL14798483 0.81 CYP19A1 (0.39) CYP19A1PDE4APDE4BPDE4CPDE4D
SCHEMBL5364834 0.81 SMN1; SMN2 (0.58) NEU3MEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL14799306 0.81 TSHR (0.47) PDE4APDE4BPDE4CPDE4DNR1H4
SCHEMBL14799138 0.81 CYP19A1 (0.59) CYP19A1PDE4APDE4BPDE4CPDE4D
SCHEMBL14799247 0.81 CYP19A1 (0.59) CYP19A1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013087749-A1 POTENTIATION INDUCED BY PDE4 INHIBITORS IN THE TREATMENT OF LEUKEMIA CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-20 WO claimed
US-20240166605-A1 PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR CHIESI FARMACEUTICI S.P.A. (IT) 2024-05-23 US disclosed
EP-3829641-B1 NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION CHIESI FARM SPA (IT) 2024-05-22 EP disclosed
US-11981639-B2 Process for the preparation of a PDE4 inhibitor CHIESI FARMACEUTICI S.P.A. (IT) 2024-05-14 US disclosed
CN-112469443-B Novel carrier particles for dry powder formulations for inhalation 奇斯药制品公司 2024-04-16 CN disclosed
EP-3587400-B1 PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR CHIESI FARM SPA (IT) 2024-03-20 EP disclosed
US-11813360-B2 Carrier particles for dry powder formulations for inhalation CHIESI FARMACEUTICI S.P.A. (IT) 2023-11-14 US disclosed
EP-4059921-A1 PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR Chiesi Farmaceutici S.p.A. (IT) 2022-09-21 EP disclosed
US-20220218678-A1 USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS CHIESI FARMACEUTICI S.P.A. (IT) 2022-07-14 US disclosed
CN-114621139-A Process for the preparation of PDE4 inhibitors 奇斯药制品公司 2022-06-14 CN disclosed
US-9056176-B2 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-16 US disclosed
WO-2015059050-A1 PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR CHIESI FARMACEUTICI S.P.A. (IT) 2015-04-30 WO disclosed
US-20150111931-A1 PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR CHIESI FARMACEUTICI S.P.A. (IT) 2015-04-23 US disclosed
US-20140378423-A1 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-25 US disclosed
US-8648204-B2 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2014-02-11 US disclosed
WO-2013087749-A1 POTENTIATION INDUCED BY PDE4 INHIBITORS IN THE TREATMENT OF LEUKEMIA CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-20 WO disclosed
US-20130156865-A1 POTENTIATION INDUCED BY PDE4 INHIBITORS IN THE TREATMENT OF LEUKEMIA CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-20 US disclosed
EP-2600829-A2 PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR Chiesi Farmaceutici S.p.A. (IT) 2013-06-12 EP disclosed
US-20130012487-A1 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-01-10 US disclosed
WO-2012016845-A2 PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR CHIESI FARMACEUTICI S.P.A. (IT) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166605-A1 PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR PDE4A, PDE12, PDE4B CYP19A1 939/4885PDE4A 1/4885PDE4B 3/4885
US-20130012487-A1 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE3A CYP19A1 1081/4885PDE4A 1/4885PDE4B 2/4885
US-20220218678-A1 USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS CFTR, CLIC1, CLCN2 CYP19A1 4668/4885PDE4A 271/4885PDE4B 397/4885
US-20140378423-A1 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE3A CYP19A1 1081/4885PDE4A 1/4885PDE4B 2/4885
US-11981639-B2 Process for the preparation of a PDE4 inhibitor PDE4A, PDE12, PDE4B CYP19A1 939/4885PDE4A 1/4885PDE4B 3/4885
US-20130156865-A1 POTENTIATION INDUCED BY PDE4 INHIBITORS IN THE TREATMENT OF LEUKEMIA PDE4A, PDE4B, PDE4D CYP19A1 2801/4885PDE4A 1/4885PDE4B 2/4885
US-20150111931-A1 PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR PDE4A, PDE12, PDE4B CYP19A1 939/4885PDE4A 1/4885PDE4B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.